Medx Health Corp

MedX Health Corp has a negative equity position of CAD -8.52 million and a debt-to-equity ratio of -0.82, indicating a leveraged capital structure with liabilities exceeding assets. The company’s liquidity is constrained, as evidenced by a current ratio of 0.1 and negative operating and free cash flows of CAD -2.51 million and CAD -3.61 million, respectively. Profitability metrics are weak, with a net loss of CAD -3.65 million and an operating loss of CAD -3.65 million, resulting in a negative return on equity of 4.29% and a negative return on assets of -4.13%. Gross profit of CAD 194,230 represents 39.6% of revenue, below the typical gross margin for medical device firms, suggesting cost or pricing pressures. The company operates as a single business segment, with no disclosed geographic revenue breakdown. However, its telemedicine platform, DermSecure, implies potential for digital scalability, though current revenue concentration remains opaque. Revenue of CAD 489,700 in the latest period reflects a challenging growth trajectory, with no prior-year data provided for comparison. Analysts have assigned a mean price target of CAD 0.28, implying a 460% upside from the current market price of CAD 0.05, though this is based on a single "buy" recommendation with no strong buy or hold ratings. Risk factors include high leverage, negative equity, and liquidity constraints, with a key flag noting negative net cash after subtracting total debt. Dilution risk is assessed as low, with no near-term pressure from share issuance or convertible debt. Recent filings and transcripts are not provided in the input data, so no specific events can be cited for the company’s recent operational or strategic developments.